# A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07535463/  
OnCo record `nct07535463` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ivonescimab in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535463 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 53 participants, started 2026-04-10 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Stereotactic Radiosurgery. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: identify the Recommended Phase 2 Dose (RPD2); intracranial progression-free survival (iPFS),. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small cell lung cancer, including squamous and non-squamous histologies". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07535463
- Phase: 1/2
- Setting: Safety and Efficacy of Ivonescimab and Chemotherapy Plus Stereotactic Radiosurgery (SRS) in the Treatment of Non-Small Cell Lung Cancer Brain Metastases
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT07535463: https://clinicaltrials.gov/study/NCT07535463

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07535463.json